INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMPNEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited (“Immutep” or the “Company”) (
NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, May 12, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (“Immutep” or “the Company”) (
NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the American Depositary Receipts (“ADRs”) of Immutep Limited (“Immutep” or the “Company”) (
NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive.
IMMUTEP ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Immutep Ltd. and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Immutep (IMMP) To Contact Him Directly To Discuss Their Options
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (“Immutep” or “the Company”) (
NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
IMMUTEP LIMITED (IMMP) INVESTOR ALERT Investors With Large Losses in Immutep Limited Should Contact Bernstein Liebhard LLP To Discuss Their RightsNEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the American Depositary Receipts (“ADRs”) of Immutep Limited (“Immutep” or the “Company”) (
NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive.
IMMP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Immutep To Contact Him Directly To Discuss Their Options
Rosen Law Firm Urges Immutep Ltd. (NASDAQ: IMMP) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Receipts (“ADRs”) of Immutep Ltd. (
NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep describes itself as an “Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases.”
Investor Notice: Robbins LLP Informs Investors of the Immutep Limited Class ActionRobbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (
NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. The company’s product pipeline includes TACTI-004, which is in phase III clinical trial evaluating eftilagimod alfa (efti) in patients with advanced lung cancer.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMPNEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited (“Immutep” or the “Company”) (
NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMPNEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited (“Immutep” or the “Company”) (
NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMPNEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited (“Immutep” or the “Company”) (
NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMPNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited (“Immutep” or the “Company”) (
NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMPNEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited (“Immutep” or the “Company”) (
NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immutep Limited (“Immutep” or “the Company”) (
NASDAQ: IMMP) for violations of the securities laws.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMPNEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited (“Immutep” or the “Company”) (
NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation – IMMP
Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Immutep Ltd. (
NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially misleading business information to the investing public.
SurgePays (NASDAQ: SURG) Expands Growth Strategy – New Lead-Driver to Boost Fintech Revenue – More Stocks InsideSurgePays, Inc. (
NASDAQ: SURG), a rapidly expanding technology and telecommunications company serving the prepaid and underserved consumer markets, released an update highlighting its multi-vertical growth strategy designed to scale revenue across wireless, fintech, and retail partner ecosystems. The company confirmed that Lifeline Wireless remains the fastest path to near-term profitability, while its prepaid brand LinkUp Mobile, HERO MVNE services , prepaid fintech top-up platform , and ClearLine SaaS retail media network form the backbone of its 2026 and long-term expansion plans.
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod AlfaSydney, Australia/Hyderabad, India, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, and along with its subsidiaries, hereafter referred to as “Dr. Reddy’s”), today announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy’s Laboratories SA, have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China.
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung CancerSYDNEY, AUSTRALIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a patient enrolment update for the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and chemotherapy as first line treatment for advanced or metastatic non-small cell lung cancer (1L NSCLC).
Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung CancerSYDNEY, AUSTRALIA, May 15, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that a 60.8% response rate and 90.2% disease control rate, according to RECIST1.1, has been achieved in the investigator-initiated INSIGHT-003 trial as of the data-cut off date of 06 May 2025. INSIGHT-003 is evaluating eftilagimod alpha (efti) in combination with the anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) and doublet chemotherapy as first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer (1L NSCLC).
